Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease

被引:3
|
作者
Baldaranov, Dobri [1 ]
Garcia, Victoria [1 ]
Miller, Garrett [1 ]
Donohue, Michael C. [1 ]
Shaw, Leslie M. [2 ]
Weiner, Mike [3 ,4 ,5 ,6 ,7 ]
Petersen, Ronald C. [8 ]
Aisen, Paul [1 ]
Raman, Rema [1 ]
Rafii, Michael S. [1 ]
机构
[1] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego 9860 Mesa Rim Rd, San Diego, CA 92121 USA
[2] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA
[3] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[8] Mayo Clin, Dept Neurol, Mayo Clin Study Aging, Mayo Clin Neurol & Neurosurg,Alzheimers Dis Res Ct, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
adverse effects; Alzheimer's disease; biomarker; brain volume; cerebrospinal fluid; lumbar puncture; pain relief medication; MULTICENTER; BIOMARKERS;
D O I
10.1002/dad2.12431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionLumbar puncture (LP) to collect and examine cerebrospinal fluid (CSF) is an important option for the evaluation of Alzheimer's disease (AD) biomarkers but it is not routinely performed due to its invasiveness and link to adverse effects (AE). MethodsWe include all participants who received at least one LP in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study. For comparison between groups, two-sample t-tests for continuous, and Pearson's chi-square test for categorical variables were performed. ResultsTwo hundred twenty-seven LP-related AEs were reported by 172 participants after 1702 LPs (13.3%). The mean age of participants who reported at least one AE was 69.79 (standard deviation (SD) 6.3) versus none 72.44 (7.17) years (p < 0.001) with female predominance (115/172 = 67.4% vs 435/913 = 48%), and had greater entorhinal cortical thickness and hippocampal volume (3.903 (0.782) vs 3.684 (0.775) mm, p = 0.002; 7.38 (1.06) vs 7.05 (1.15) mm(3), p < 0.001), respectively. DiscussionWe found that younger age, female sex, and greater thickness of the entorhinal cortex were associated with a higher rate of LP-related AE reports.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Factors Influencing Successful Lumbar Puncture in Alzheimer Research
    Moulder, Krista L.
    Besser, Lilah M.
    Beekly, Duane
    Blennow, Kaj
    Kukull, Walter
    Morris, John C.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2017, 31 (04): : 287 - 294
  • [12] Lumbar puncture safety and tolerability in premanifest and manifest Huntington's disease: a multi-analysis cross-sectional study
    Hassan, Yara Refaat
    Rodrigues, Filipe Brogueira
    Zeun, Paul
    Byrne, Lauren M.
    Estevez-Fraga, Carlos
    Tortelli, Rosanna
    Scahill, Rachael, I
    Wild, Edward J.
    Tabrizi, Sarah J.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [13] Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?
    Menendez-Gonzalez, Manuel
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [14] Original Public acceptability of lumbar puncture in the diagnosis of Alzheimer's disease: a questionnaire-based single center study in China
    Guo, Xiaojuan
    Gao, Ling
    Liu, Jie
    Lu, Wenhui
    Wang, Jin
    Qu, Qiumin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (06): : 4179 - 4187
  • [15] Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
    Darreh-Shori, Taher
    Jelic, Vesna
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (01) : 167 - 176
  • [16] A controlled lumbar puncture procedure improves the safety of lumbar puncture
    Li, Chun
    Li, Miaomiao
    Wang, Yixian
    Li, Shaoyi
    Cong, Lin
    Ma, Weining
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [17] Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
    Prakash, Neha
    Caspell-Garcia, Chelsea
    Coffey, Christopher
    Siderowf, Andrew
    Tanner, Caroline M.
    Kieburtz, Karl
    Mollenhauer, Brit
    Galasko, Douglas
    Merchant, Kalpana
    Foroud, Tatiana
    Chahine, Lana M.
    Weintraub, Daniel
    Casaceli, Cindy
    Dorsey, Ray
    Wilson, Renee
    Herzog, Margaret
    Daegele, Nichole
    Arnedo, Vanessa
    Frasier, Mark
    Sherer, Todd
    Marek, Ken
    Frank, Samuel
    Jennings, Danna
    Simuni, Tanya
    Marek, Kenneth
    Siderowf, Andrew
    Seibyl, John
    Coffey, Christopher
    Tanner, Caroline
    Tosun-Turgut, Duygu
    Simunir, Tanya
    Shaw, Leslie
    Trojanowski, John
    Singleton, Andrew
    Kieburtz, Karl
    Toga, Arthur
    Mollenhauer, Brit
    Galasko, Douglas
    Poewe, Werner
    Foroud, Tatiana
    Poston, Kathleen
    Sherer, Todd
    Chowdhury, Sohini
    Frasier, Mark
    Kopil, Catherine
    Arnedo, Vanessa
    Daegele, Nichole
    Casaceli, Cynthia
    Dorsey, Ray
    Wilson, Renee
    PARKINSONISM & RELATED DISORDERS, 2019, 62 : 201 - 209
  • [18] Safety and Usefulness of Lumbar Puncture for the Diagnosis and Management of Young-Onset Cognitive Disorders
    Soo, See Ann
    Zailan, Fatin Zahra
    Tan, Jayne Yi
    Sandhu, Gurveen Kaur
    Wong, Benjamin Yi Xin
    Wang, Brian Zhiyang
    Ng, Adeline Su Lyn
    Chiew, Hui Jin
    Ng, Kok Pin
    Kandiah, Nagaendran
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 87 (01) : 479 - 488
  • [19] Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials
    Farlow M.R.
    Graham S.M.
    Alva G.
    Drug Safety, 2008, 31 (7) : 577 - 585
  • [20] Safety tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
    Sramek, JJ
    Anand, R
    Wardle, TS
    Irwin, P
    Hartman, RD
    Cutler, NR
    LIFE SCIENCES, 1996, 58 (15) : 1201 - 1207